News
Novartis’ Vanrafia (atrasentan) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat ...
Pharmaceutical Technology on MSN16d
FDA grants accelerated approval to Novartis’ Vanrafia for IgANThe approval is supported by a prespecified interim analysis from the ongoing, randomised Phase III ALIGN trial.
The Food and Drug Administration (FDA) has granted accelerated approval to Vanrafia ® (atrasentan) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid ...
Richard Lafayette, MD, FACP, Stanford University Medical Center, explains the significance of this second approval in a month ...
Amid all the volatility, some companies are proving resilient by performing much better than the market. Some of these look ...
NEW HYDE PARK, N.Y., April 07, 2025 (GLOBE NEWSWIRE) -- CareMed, an independent specialty pharmacy, is in the Limited Distribution Network for Vanrafia™ (atrasentan), for the reduction of ...
As targeted treatments such as Tarpeyo (Calliditas), Filspari (Travere), Fabhalta (Novartis), and most recently Vanrafia (Novartis) enter the market, this research captures how patients are navigating ...
Su principio activo, atrasentan, ha sido desarrollado por la compañía estadounidense Chinook Therapeutics adquirida por Novartis en 2023 por 3.200 millones de dólares. 'Vanrafia' está indicado ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback